Science Simplified!

Comment

Comment by Dr. Krishna Kumari Challa 10 hours ago

A common food compound may hold the key to shutting down leaky gut damage

When the intestinal lining breaks down, harmful gut bacterial antigens can slip into the bloodstream alongside nutrients. This breach in the gut's protective barrier, known as "leaky gut," is more than a digestive issue—it's a sign of inflammatory bowel disease (IBD) and has been increasingly linked to a number of chronic conditions.
A team of researchers has uncovered a key mechanism underlying leaky gut and identified a promising and natural way to repair it. And a potential solution is already in many of the foods we eat every day.

In a study published in the journal Nature Communications, the team shares how phytic acid (or InsP6), a natural compound found in whole grains, beans, lentils, nuts, and seeds, plays an important role in maintaining the integrity of the intestinal barrier.

Phytic acid is something many people already consume daily, especially in plant-rich diets.It's beyond just a dietary component; it also functions as a biologically active molecule that supports gut health.
Phytic acid (InsP6), a compound found in whole grains, beans, lentils, nuts, and seeds, directly activates histone deacetylase 3 (HDAC3), a regulator essential for maintaining intestinal barrier integrity. This mechanism protects against gut barrier breakdown and inflammation associated with leaky gut and inflammatory bowel disease, suggesting potential for targeted supplementation therapies.

Sujan Chatterjee et al, Phytic acid (InsP6) activates HDAC3 epigenetic axis to maintain intestinal barrier function, Nature Communications (2026). DOI: 10.1038/s41467-026-68994-0

Comment by Dr. Krishna Kumari Challa 10 hours ago

One-time gene editing treatment lowers 'bad' cholesterol by up to 62%
A single infusion of the gene editing therapy VERVE-102 reduced LDL cholesterol by up to 62% in adults with inherited high cholesterol or premature coronary artery disease, with effects lasting up to 18 months. No serious adverse events were observed at the highest dose, and only mild, transient infusion reactions and liver test changes occurred. Larger studies are ongoing to confirm safety and efficacy.

Scott B. Vafai et al, In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia, New England Journal of Medicine (2026). DOI: 10.1056/nejmoa2601283

Comment by Dr. Krishna Kumari Challa 10 hours ago

some chikungunya virus infections may turn chronic

Chikungunya virus, which is transmitted to people by infected Aedes mosquitoes and characterized by high fever and intense joint swelling and pain, has made a resurgence in many countries around the world in recent years.

Researchers estimate that about half of people infected with chikungunya virus will progress to a chronic form of the disease and experience relapsing arthralgia and arthritis that can span years and currently has no treatment.
Chikungunya virus can persist in joint-associated macrophages, which act as reservoirs, leading to chronic joint pain and inflammation in about half of infected individuals. Advanced sequencing techniques identified these macrophages as harbouring viral RNA, and antiviral treatment targeting viral replication reduced chronic inflammation, indicating persistent infection in these cells drives chronic symptoms.

Kristen M. Zarrella et al, Chikungunya virus persists in joint-associated macrophages and promotes chronic disease in mice, Nature Microbiology (2026). DOI: 10.1038/s41564-026-02303-9

Comment by Dr. Krishna Kumari Challa 10 hours ago

The Y chromosome is home to surprising jumping genes

The humble Y chromosome may be the smallest chromosome in the mammalian genome (and getting even smaller), but it is mighty: Genes on the Y chromosome are critical for fertility in males.

In a new study in the journal Current Biology, researchers have studied deer mice to outline how the Y chromosome defends itself against decay by acquiring gene families, holding its own to maintain fertility.
A gene family named Phf8y was identified on the Y chromosome of deer mice, originating from the X-linked Phf8 gene via transposable element-mediated duplication. This represents a rare case of a gene moving from the X chromosome to an autosome and then to the Y chromosome. Such gene acquisitions may help the Y chromosome maintain essential functions for male fertility and contribute to the evolutionary stability of sex ratios.

Autosomes are all of the chromosomes that aren't the sex chromosomes. However, the Y chromosome is often thought of as a place where genes go to die because its genes don't recombine.
In this study, researchers discovered a gene family, which they named Phf8y, that bucked this trend, hopping to the Y and duplicating itself.
It's a unique pattern that they didn't expect—having a gene move from the X chromosome to an autosome to the Y chromosome.
What's driving the process? In the production of sperm, the X chromosome from the maternal side and the Y chromosome from the paternal side result in a sperm cell that has either an X or Y chromosome.

During this period, the X serves as a sort of autosome for genes important for viability and spermatogenesis, Mueller explains.
But since males carry just one X, an alternative method arose evolutionarily to provide a way to back up important genes for creating sperm.
It's like having your own clone around who can jump in when you've gone on vacation.
There are genes that copy themselves, called transposable elements. They hide out in our genome and are activated on rare occasions. In fact, these so-called jumping genes make up half of the human genome.

The team discovered that the deer mouse Phf8y on the Y chromosome is derived from the X-linked Phf8, apparently having hijacked the transposable element machinery to make an extra copy of itself.

What Phf8y is doing is still a mystery.

The team speculates that this gene on the Y chromosome is involved in chromatin packing, or how DNA is packaged, and could confer an edge to Y-bearing sperm to compete with X-bearing sperm.

Previous studies in house mice have revealed genes that share similar features to Phf8y and are in an X–Y arms race.

Ivan F. Mier et al, An X-to-autosome-to-Y chromosome amplified retrogene family functions in spermatids, Current Biology (2026). DOI: 10.1016/j.cub.2026.04.045

Comment by Dr. Krishna Kumari Challa 10 hours ago

Wounds may trigger 'aged' cells within hours, reshaping how senescence starts
Cells can enter senescence within minutes to hours after injury, using pre-existing mRNA to rapidly produce p21 protein, independent of new gene transcription. This early senescence actively coordinates wound healing by releasing signaling molecules and guiding cell migration, but is beneficial only during a narrow time window and is eliminated after healing. Persistent senescent cells are linked to age-related diseases.

Karla Valdivieso et al, Transcription-independent induction of rapid-onset senescence is integral to healing, Nature Cell Biology (2026). DOI: 10.1038/s41556-026-01948-2

Comment by Dr. Krishna Kumari Challa 10 hours ago

AI is making journalistic language more repetitive and predictable—and it's a problem for all of us
Increased use of AI-generated text in journalism leads to more repetitive, predictable, and homogenized language, reducing linguistic diversity and innovation. This shift limits the press's traditional role in introducing new vocabulary and nuanced expression, potentially reinforcing existing biases and diminishing the public's capacity for precise communication and debate. Mixing synthetic and human-generated text can mitigate these effects, but large-scale replacement of human writing risks long-term decline in public language richness.

original article.

Comment by Dr. Krishna Kumari Challa on Sunday

Despite such striking results, reprogramming the immune system is no simple matter. In early treatment of cancer patients, CAR T cells produced life-threatening side effects, as outlined in a 2026 article in the Annual Review of Medicine. As CAR T cells attack their targets, the associated inflammation can cause symptoms like high fevers and low blood pressure. If that inflammation reaches the brain, it can cause additional problems such as confusion and drowsiness.

Fortunately, physicians now have a decade's worth of experience recognizing and treating these problems. They're certainly reversible and don't cause long-term damage most of the time.
Physicians and patients also must contend with decreased immunity as both a side effect of the treatment and its desired outcome. In CAR T treatment, doctors typically use powerful chemotherapy drugs to temporarily reduce the body's immune cell population to make room for the new, engineered cells, leaving patients temporarily immunosuppressed. And if the treatment works, it will decimate B cell populations. Patients can be vulnerable to infections for up to a year after treatment.
These effects are manageable with preventive antibiotics, antivirals and vaccines. Patients also retain antibodies that their B cells made before the treatment, which provide residual protection for a few months. And for reasons that are not yet fully understood, CAR T seems to leave older B cells, which provide immune memory of past infections, intact in some cases. One study found that autoimmune patients treated with CAR T still made antibodies for diseases they'd been previously vaccinated against, like chicken pox and measles. These are signs that the treatment did not completely return the immune system to its factory settings.

When evaluating CAR T risk, it's important to consider that many existing treatments for autoimmune disease also suppress the immune system for as long as a person takes them, experts note.
Researchers are already working on second- and third-generation versions of CAR T that they expect to be safer for both cancer and autoimmunity.

Source: https://knowablemagazine.org/content/article/health-disease/2026/ca...

Part 2

Comment by Dr. Krishna Kumari Challa on Sunday

CAR T moves beyond cancer, targeting autoimmune disease with immune system reset
CAR T cell therapy, originally developed for cancer, is being investigated for autoimmune diseases by targeting and eliminating pathogenic B cells, potentially resetting immune function. Early trials show promising symptom improvement and reduced need for other immunotherapies, but risks include severe inflammation, immunosuppression, and uncertain long-term effects such as secondary malignancies. Newer approaches aim to enhance safety and reduce costs, including mRNA-based CAR T and off-the-shelf donor cell therapies. Long-term efficacy and safety in autoimmunity remain under investigation.

Originally designed to target and wipe out cancer by reprogramming the patient's immune cells, CAR T is now being offered to patients in hundreds of clinical trials for autoimmune conditions like multiple sclerosis, lupus, Graves' disease, vasculitis and many others. The hope is that CAR T can duplicate the success it has demonstrated in a range of blood cancers by hunting down and eliminating cells that target the self in autoimmune diseases. This would essentially reset the body's defenses to a state like the one that existed before the disease took hold.
But along with CAR T's promise come risks, questions and challenges. There's uncertainty about how well it will work for autoimmunity and how long any benefits might last, as well as what long-term side effects might arise.
The basic premise of CAR T is to activate the power of key immune cells called T cells. T cells normally recognize other cells that have been infected by a virus or bacterium, or are otherwise abnormal, and either destroy them or recruit other parts of the immune system to do so.

In CAR T for cancer, scientists engineer those T cells to specifically hunt and destroy malignant cells. The technology got its start when cancer researchers figured out how to take out a patient's own T cells, insert DNA instructions for a "chimeric antigen receptor," or CAR, and put them back into the person's circulation. The CAR, which sits on the T cell's surface and latches on to a specific molecular partner on the surface of cancerous cells, activates the T cell to attack.

Today CAR T cells are most commonly programmed to attack B cells, another key immune player. B cells are normally responsible for making antibodies, but in certain blood cancers, they proliferate out of control. By giving T cells a CAR that recognizes one of a couple of molecules unique to the B cell surface, the cells are reprogrammed to find and eliminate those cancerous cells.

B cells are also the central problem in many autoimmune conditions: They mistakenly make antibodies against normal tissues instead of against invading pathogens. So as CAR T began to succeed against B cell cancers, it didn't take long for doctors to reason that CAR T therapy might also be able to wipe out bad B cells in people with autoimmunity.
A German team pioneered autoimmune CAR T in a woman with lupus, reporting positive results in 2021. Since then, that team and others have worked to translate the oncology success of CAR T to tackle a broad spectrum of autoimmune diseases.
Part 1

Comment by Dr. Krishna Kumari Challa on Saturday

The left and right ventricles differ in their ability to withstand the effects of cardiac arrest, study finds
The right ventricle demonstrates greater resistance to ischemia and better preservation of electrical activity than the left ventricle during cardiac arrest caused by ventricular fibrillation. Electrical gradients between heart regions can be detected via surface ECG, which may help predict neurological recovery outcomes. These findings suggest potential for targeted therapies to improve left ventricular resistance during cardiac arrest.

https://medicalxpress.com/news/2026-05-left-ventricles-differ-abili...

Comment by Dr. Krishna Kumari Challa on Saturday

What separates dreaming from deep sleep? Brain rhythm offers new clue to consciousness

Neuropsychology researchers have discovered a rhythm in the midbrain that could serve as a biophysiological signature for specific states of consciousness.
A rapid oscillation in the human thalamus, occurring at 20–45 Hz, is present only during wakefulness and REM sleep, but absent during non-REM sleep. This thalamic rhythm may serve as a biophysiological marker distinguishing conscious states from deep, unconscious sleep.
The thalamus is a deep-lying structure in the center of the brain which gathers and relays signals from many different areas of the brain. It functions like a gate for perception and attention and is thought to play a key role in supporting conscious states.
The researchers discovered a previously unknown rapid activity pattern in the human thalamus.
This rapid oscillation, in the frequency range of 20 to 45 Hertz, occurs exclusively during waking hours and REM sleep, the phase of sleep with rapid eye movements and intensive dreams. It is entirely absent in non-REM sleep, when eye movements are absent and consciousness is strongly reduced. In this sleep phase, the brain activity is dominated instead by slower oscillations.
The results show that the central thalamus plays an important role in regulating brain states. In the context of existing research, our results show that this small deep-lying brain structure could actively influence our states of consciousness.
These characteristic rhythm patterns can be reliably attributed to specific states and thus have the potential to serve as a measurable biological signature of states of consciousness.

Aditya Chowdhury et al, Thalamic oscillations distinguish natural states of consciousness in humans, Nature Human Behaviour (2026). DOI: 10.1038/s41562-026-02446-z

• ‹ Previous
• 1
• 2
• 3
• …
• 1241
• Next ›
• Page